CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors
NCT ID: NCT00949624
Last Updated: 2012-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
50 participants
INTERVENTIONAL
2005-12-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
NCT00454649
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
NCT07229586
APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies
NCT03386526
AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors
NCT00372736
AEG35156 and Docetaxel in Treating Patients With Solid Tumors
NCT00357747
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
60 mg BID/ 75 mg/m2
CP-868,596
Oral tablet 60 mg BID continuous
Docetaxel
Intravenous 75 mg/m2 every three weeks
Cohort 2
100 mg BID/75 mg/m2
CP-868,596
Oral tablet 100 mg BID continuous
Docetaxel
Intravenous 75 mg/m2 every three weeks
Cohort 3
100 mg BID/100 mg/m2
CP-868,596
Oral tablet 100 mg BID continuous
Docetaxel
Intravenous 100 mg/m2 every three weeks
Cohort 4b
CP-868,596 + AG-013736 + TXT 75
CP-868,596
Oral tablet 60 mg BID continuous
AG-013736
Oral tablet 5 mg BID continuous
Docetaxel
Intravenous 75 mg/m2 every three weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CP-868,596
Oral tablet 60 mg BID continuous
Docetaxel
Intravenous 75 mg/m2 every three weeks
CP-868,596
Oral tablet 100 mg BID continuous
Docetaxel
Intravenous 75 mg/m2 every three weeks
CP-868,596
Oral tablet 100 mg BID continuous
Docetaxel
Intravenous 100 mg/m2 every three weeks
CP-868,596
Oral tablet 60 mg BID continuous
AG-013736
Oral tablet 5 mg BID continuous
Docetaxel
Intravenous 75 mg/m2 every three weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with primary brain tumors are not eligible.
* Have at least one site of measurable disease.
Exclusion Criteria
* Received tamoxifen within 4 weeks prior to study entry.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arog Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Durham, North Carolina, United States
Pfizer Investigational Site
East Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5301005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.